KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Capital Leases (2023 - 2026)

Castle Biosciences' Capital Leases history spans 3 years, with the latest figure at $314000.0 for Q4 2025.

  • On a quarterly basis, Capital Leases rose 0.96% to $314000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $314000.0, a 0.96% increase, with the full-year FY2025 number at $314000.0, up 0.96% from a year prior.
  • Capital Leases hit $314000.0 in Q4 2025 for Castle Biosciences, down from $339000.0 in the prior quarter.
  • Over the last five years, Capital Leases for CSTL hit a ceiling of $364000.0 in Q2 2025 and a floor of $25000.0 in Q4 2023.
  • Historically, Capital Leases has averaged $285250.0 across 3 years, with a median of $313000.0 in 2024.
  • Biggest five-year swings in Capital Leases: surged 1144.0% in 2024 and later rose 0.96% in 2025.
  • Tracing CSTL's Capital Leases over 3 years: stood at $25000.0 in 2023, then surged by 1144.0% to $311000.0 in 2024, then increased by 0.96% to $314000.0 in 2025.
  • Business Quant data shows Capital Leases for CSTL at $314000.0 in Q4 2025, $339000.0 in Q3 2025, and $364000.0 in Q2 2025.